Vaccine Evaluation Group
About the Group
The Vaccine Evaluation Group is dedicated to every stage of vaccine research, from initial clinical trials to comprehensive program assessments, specializing in developing and conducting first-in-human phase 1 studies, as well as post-licensure phase 4 trials. The Evaluation Group works with external partners to evaluate the real-world effectiveness of vaccines, examining their impact on disease burden, vaccine compliance, and public acceptance.
The Group plays a key role in the Center’s integrated, multi-disciplinary vaccine research approach, partnering closely with industry, external organizations, and the Vaccine Discovery and the Policy, Programs and Implementation (PPI) Groups to drive innovation and public health progress.
Areas of Expertise
- Development and implementation of clinical vaccine trials, ranging from first-in-human phase 1 clinical trials to post-licensure phase 4 trials
- Clinical Human Infection Model (CHIM) trials
- Field effectiveness of vaccines
- Vaccine effects on disease burden
- Specialization in early phase, first-in-human vaccine clinical trials, conducting more than 25 in the Center’s 15-year history
- Clinical trials in special populations such as seniors, infants, pregnant individuals, and those with existing medical conditions
Research Group Members
- Andrew, Melissa(Dalhousie)
- Bowles, Susan(NSH)
- Comeau, Jeannette(Dalhousie)
- Davis, Ian(Dalhousie)
- Di Cara, Francesca(Dalhousie)
- Halperin, Scott(Dalhousie)
- Hatchette, Todd(Dalhousie)
- Isenor, Jennifer(Dalhousie)
- Langley, Joanne(Dalhousie)
- LeBlanc, Jason(Dalhousie)